Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers
- 10 November 2009
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 208 (1) , 37-44
Abstract
Rationale There is an extensive literature showing that the CB1 cannabinoid receptor antagonist rimonabant (SR141716) decreases alcohol consumption in animals, but little is known about its effects in human alcohol drinkers. Methods In this study, 49 nontreatment-seeking heavy alcohol drinkers participated in a 3-week study. After a 1-week baseline, participants received either 20 mg/day of rimonabant or placebo for 2 weeks under double-blind conditions. During these 3 weeks, participants reported their daily alcohol consumption by telephone. Subsequently, they participated in an alcohol self-administration paradigm in which they received a priming dose of alcohol followed by the option of consuming either eight alcohol drinks or receiving $3.00 for each nonconsumed drink. Endocrine measures and self-rating scales were also obtained. Results Rimonabant did not change alcohol consumption during the 2 weeks of daily call-ins. Similarly, the drug did not change either alcohol self-administration or endocrine measures during the laboratory session. Conclusion We conclude that the daily administration of 20 mg of rimonabant for 2 weeks has no effect on alcohol consumption in nontreatment-seeking heavy alcohol drinkers.Keywords
This publication has 29 references indexed in Scilit:
- Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol DependenceJournal of Clinical Psychopharmacology, 2008
- Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis2008
- Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomesJournal of Psychopharmacology, 2007
- Differences in δ- and μ-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent SubjectsNeuropsychopharmacology, 2007
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Genetic Impairment of Frontocortical Endocannabinoid Degradation and High Alcohol PreferenceNeuropsychopharmacology, 2006
- Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol‐seeking behavior in ratsEuropean Journal of Neuroscience, 2005
- Long-Lasting Increase of Alcohol Relapse by the Cannabinoid Receptor Agonist WIN 55,212-2 during Alcohol DeprivationJournal of Neuroscience, 2004
- Effects of SR141716A on Ethanol and Sucrose Self‐AdministrationAlcohol, Clinical and Experimental Research, 2001
- Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar)British Journal of Addiction, 1989